RADRETUMAB (L19-131I)

RADRETUMAB (L19-131I)

L19-131I is the radiolabeled version of the human vascular targeting antibody L19, specific to the EDB domain of fibronectin, expressed in a recombinant format called SIP (Small Immuno Protein) which has been proven to display better tumor selectivity in vivo compared to the conventional IgG format or scFv.

Following several trials in solid cancer and brain metastasis indications, this product is in planning to enter multicenter Phase II clinical trials for the therapy of Hodgkin Lymphoma.

SELECTED REFERENCES

Poli et al. (2013), Cancer Immunol Res., 1, 134-43;
Erba et al. (2012) J Nucl Med, 53, 922-927;
Lastoria et al. (2011) J Clin. Oncol., 29, e12502;
Del Conte et al. (2010) J Clin. Oncol.,  28, 2523;
Erba et al. (2010) J Clin. Oncol.,  28, e13054;
Tijink et al. (2009) Eur J Nucl Med Mol Imaging, 36, 1235-1244;
Sauer et al. (2009) Blood, 113, 2265-2274; 
Tijink et al. (2006) J. Nucl. Med., 47, 1127-1135;
Berndorff et al. (2005) Clin. Cancer Res., 11, 7053-7063;